Liver injury with Ocrevus® (ocrelizumab)

A Dear Healthcare Professional Letter has been issued by Roche Singapore Pte Ltd to inform healthcare professionals that following a recent data review, clinically significant liver injury without findings of viral hepatitis has been classified as an identified risk for Ocrevus® (ocrelizumab), with reasonable evidence showing a temporal association with the first administration of ocrelizumab. Healthcare professionals are advised to counsel patients on the risks and benefits of ocrelizumab, conduct liver function tests prior to initiating treatment with ocrelizumab and monitor patients for signs and symptoms of any hepatic injury during treatment. Liver function tests should be performed promptly in patients who report symptoms that may indicate liver injury and if liver injury is present, ocrelizumab should be discontinued. In the event that an alternative etiology is identified, treatment with ocrelizumab can be resumed only when the liver injury has fully resolved. The local product information will be updated accordingly. Please refer to the letter for details.

Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

28 Jul 2025

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.